Key result
Combined administration of pioglitazone and adipose-derived regenerative cells significantly improved left ventricular ejection fraction and survival in a rat myocardial infarction model.
Why the study?
Cell transplantation efficacy in heart failure is modest, and it was hypothesized that combining PPARgamma agonists with adipose-derived regenerative cells would enhance adiponectin paracrine effects and functional recovery in chronic myocardial infarction.
Does combined administration of pioglitazone and adipose-derived regenerative cells improve cardiac function in a rat model of ischemic cardiomyopathy?
Does combined administration of pioglitazone and adipose-derived regenerative cells improve cardiac function in a rat model of ischemic cardiomyopathy?
p-value: p=<0.05
Combined administration of pioglitazone and adipose-derived regenerative cells enhances adiponectin paracrine effects, promotes M2 macrophage polarization, and improves cardiac function in a rat model of myocardial infarction.
Hypothesis-generating in rat MI models; leaves open translation of combined ADRC-pioglitazone therapy to human ischemic cardiomyopathy.
BACKGROUND: The efficacy of cell transplantation in heart failure is reportedly modest, but adjuvant drugs combined with cell therapy may improve this efficacy. Peroxisome proliferator-activated receptor (PPAR)γ, one of the hypoglycemic medicine for diabetes mellitus, reportedly enhances cytokine production in adipose tissue-derived regenerative cells (ADRCs). We hypothesized that combined administration of PPARγ agonists and ADRCs may enhance the paracrine effects of adiponectin (APN), leading to functional recovery in a chronic myocardial infarction (MI) model. METHODS: ADRCs were isolated from adipose tissues of adult rats by gradient centrifugation and embedded in bio-compatible fibrin-glue to produce ADRCs grafts. In the in vitro study, the ADRCs grafts released APN, which was significantly enhanced by the PPARγ agonist (PGZ, pioglitazone). Transplantation of ADRCs grafts (group A), ADRCs mixed with PGZ (group AP), APN knockdown-ADRCs (group Si) or PGZ (group P) onto the epicardium or a sham operation (group C) was performed (n = 10-20 per group). RESULTS: The AP group showed significant improvement in ejection fraction compared to that in the other groups. In the AP group, a significantly larger number of M2-polarized macrophages was detected and existed for a significantly longer duration in the infarct area. Furthermore, comparing Si group and P group, western blotting of T-cadherin revealed that exogenous APN and local expression of T-cadherin were essential to this histological change and recovery of cardiac function. CONCLUSIONS: Combined administration of PPARγ agonist and ADRSCs activated M2-polarized macrophages with enhancement of APN paracrine effects and lead to better cardiac function in a rat infarction model.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2019) studied Ischemic cardiomyopathy (n=72). Adipose-derived regenerative cells combined with pioglitazone vs. Fibrin only (sham), ADRCs alone, or APN knockdown ADRCs was evaluated on Left ventricular ejection fraction (p=<0.05). Combined administration of pioglitazone and adipose-derived regenerative cells significantly improved left ventricular ejection fraction and survival in a rat myocardial infarction model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: